Tvardi Therapeutics, Inc. (NASDAQ:TVRD) Given Average Rating of “Moderate Buy” by Analysts

Tvardi Therapeutics, Inc. (NASDAQ:TVRD) has been assigned a consensus recommendation of “Moderate Buy” from the eight ratings firms that are covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation, three have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $39.80.

Several research firms have weighed in on TVRD. BTIG Research reiterated a “buy” rating and set a $15.00 price target on shares of Tvardi Therapeutics in a research note on Wednesday, April 1st. HC Wainwright initiated coverage on Tvardi Therapeutics in a report on Monday, June 8th. They issued a “buy” rating and a $9.00 price target for the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tvardi Therapeutics in a report on Friday, April 10th. Finally, Wall Street Zen cut Tvardi Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, April 4th.

Hedge Funds Weigh In On Tvardi Therapeutics

A number of large investors have recently bought and sold shares of the business. JPMorgan Chase & Co. acquired a new position in Tvardi Therapeutics in the 2nd quarter worth about $39,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in shares of Tvardi Therapeutics during the second quarter valued at approximately $43,000. Headlands Technologies LLC acquired a new position in shares of Tvardi Therapeutics during the second quarter valued at approximately $80,000. New York State Common Retirement Fund acquired a new position in shares of Tvardi Therapeutics during the second quarter valued at approximately $92,000. Finally, Arax Advisory Partners raised its holdings in shares of Tvardi Therapeutics by 277.2% during the fourth quarter. Arax Advisory Partners now owns 8,400 shares of the company’s stock valued at $36,000 after acquiring an additional 6,173 shares during the last quarter. Institutional investors and hedge funds own 44.66% of the company’s stock.

Tvardi Therapeutics Stock Performance

TVRD opened at $2.64 on Wednesday. Tvardi Therapeutics has a 12 month low of $2.61 and a 12 month high of $43.65. The stock has a fifty day moving average price of $3.31 and a 200-day moving average price of $3.74. The firm has a market cap of $24.76 million, a price-to-earnings ratio of -0.85 and a beta of 0.33.

Tvardi Therapeutics (NASDAQ:TVRD) last announced its earnings results on Friday, May 8th. The company reported ($0.73) earnings per share for the quarter, missing the consensus estimate of ($0.65) by ($0.08). On average, equities research analysts forecast that Tvardi Therapeutics will post -2.39 EPS for the current year.

About Tvardi Therapeutics

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.